Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina

dc.creatorGonzález, Soledad E.
dc.creatorOlszevicki, Santiago
dc.creatorSalazar, Martín R.
dc.creatorCalabria, Ana
dc.creatorRegairaz, Lorena
dc.creatorMarín, Lupe
dc.creatorCampos, Patricia
dc.creatorVarela, Teresa
dc.creatorGonzález Martínez, Veronica V.
dc.creatorCeriani, Leticia
dc.creatorGarcia, Enio
dc.creatorKreplak, Nicolás
dc.creatorPifano, Marina
dc.creatorEstenssoro, Elisa
dc.creatorMarsico, Franco
dc.date2021-09-12
dc.date2022-09-26T15:09:33Z
dc.date.accessioned2023-07-15T04:42:47Z
dc.date.available2023-07-15T04:42:47Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/142736
dc.identifierissn:2589-5370
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7470599
dc.descriptionBackground A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our study was to investigate the association between the rollout of the first component (rAd26) of Gam-COVID-Vac and PCR-positive tests, hospitalisations and deaths. Methods We conducted a retrospective cohort study which analyzed individuals aged 60-79 who self-registered in the online vaccination system of the Province of Buenos Aires, Argentina, from December 29, 2020 to March 21, 2021. Exclusion criteria were having a previous positive RT-PCR or antigen tests for SARS-CoV-2, having received other vaccines, or two doses of any vaccine. Proportions of new laboratory-confirmed SARS-CoV-2 infections, hospitalisations and deaths until 83 days of vaccination were compared between vaccinated and unvaccinated subjects. Vaccine effectiveness for the three outcomes was calculated as (1–OR) × 100. Kaplan-Meier cumulative incidence curves were constructed. Findings During the study period 415995 registered subjects received the first component of Gam-COVID-Vac; 40387 belonged to the 60-79 age group, and were compared to 38978 unvaccinated. Vaccine effectiveness for preventing laboratory-confirmed infections was 78•6% [CI95% 74·8 - 81·7]; and for reducing hospitalizations and deaths was, respectively, 87·6% [CI95% 80·3 - 92·2] and 84·8% [CI95% 75·0 - 90·7]. Effectiveness was high across all subgroups. Interpretation Similarly to other vaccines, the administration of one dose of Gam-COVID-Vac was effective for a wide range of COVID-19–related outcomes.
dc.descriptionFacultad de Ciencias Médicas
dc.formatapplication/pdf
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.subjectCiencias Médicas
dc.subjectVaccination
dc.subjectCovid-19
dc.subjectImmunization
dc.subjectInfectious diseases
dc.titleEffectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
dc.typeArticulo
dc.typeArticulo


Este ítem pertenece a la siguiente institución